Boilerplate clauses

Boilerplate clauses

This subtopic focuses on boilerplate clauses in commercial business-to-business agreements. For information on commercial clauses more generally, see: Commercial clauses—overview.

For information on boilerplate in business-to-consumer contracts, see the section on ‘Consumer boilerplate’ below.

For information on boilerplate in public sector contracts, see the section on ‘Public sector boilerplate’ below.

The role of boilerplate

Lawyers work on a huge variety of transactions, but all of them will in some way involve written agreements. All of those agreements should contain some boilerplate clauses.

‘Boilerplate’ is the term used to describe the clauses that are included in an agreement to deal with the mechanics of how it works and those legal points that are relevant to most transactions. For further consideration of the role and importance of boilerplate clauses, see Practice Note: The role of boilerplate.

Boilerplate clauses are generally found at the beginning and the end of an agreement. Such clauses are often thought of as standard, miscellaneous provisions, but this is a very dangerous view to adopt. It is not unusual for a boilerplate clause to be the cause of litigation. Since a boilerplate clause

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

MHRA outlines new decentralised manufacturing framework

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a blog outlining the implementation of the new Decentralised Manufacturing (DM) legislation, which came into force on 23 July 2025 under the Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025, SI 2025/87.

ICH adopts new guideline on real-world data studies for medicine safety assessment

The International Council for Harmonisation (ICH) has adopted its M14 guideline. The ICH M14 guideline establishes internationally harmonised principles for the planning, design, analysis and reporting of non-interventional pharmacoepidemiological studies that use real-world data (RWD) to assess the safety of medicines. It aims to improve the reliability and regulatory acceptance of such studies by providing a structured framework that includes feasibility assessments, protocol development, data management and statistical analysis. The guideline emphasises the importance of fit-for-use data, robust study design and early engagement with regulators to ensure that evidence generated is adequate for post-marketing safety evaluations. It also outlines considerations for bias, confounding and validation of key variables and encourages transparency through public registration and dissemination of study findings.

MDCG updates borderline and classification manual under EU medical device regulations

The Medical Device Coordination Group (MDCG) has updated its manual on borderline and classification for medical devices under Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices. The September 2025 update introduces new sections addressing the qualification and classification of additional products, including red blood cell additive solutions containing adenine, dual action cream with menthol and capsaicin, lactose tablets for vaginal use, microabrasion dental stain removers, medical examination table covers and mobile sterile air systems.

ABPI publishes report on UK's position in global pharma investment

The Association of the British Pharmaceutical Industry (ABPI) has published a report that assesses the UK’s attractiveness in global pharmaceutical investment, compared with 12 other countries across four key areas: pre-clinical research, clinical trials, manufacturing and distribution, and headquarters and affiliates. The report highlights both the UK’s strengths and weaknesses in pharmaceutical investment, while identifying areas for potential growth. It also reveals a 58% decrease in life sciences foreign direct investment (FDI), falling from £1.897bn in 2021 to £795m in 2023 and investment in pharmaceutical research and development (R&D) declining by almost £100m in the same year. In response to the report, the Health Research Authority (HRA) endorsed the report and highlighted the importance of accelerating research timelines to improve patient care, noting the HRA’s active role in the UK Clinical Research Delivery (UKCRD) programme to streamline and speed up clinical trial delivery.